caa a22 4500 445336765 CHVBK 20180317142758.0 cr unu---uuuuu 170323e20110501xx s 000 0 eng 10.1245/s10434-010-1467-4 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1467-4 Combined Thermal-Surgical Ablation of Locally Advanced Abdominopelvic Malignancies [Elektronische Daten] [Csaba Gajdos, Tracey MacDermott, Martin McCarter, Nathan Pearlman] Background: Treatment options for patients with inoperable primary or recurrent/metastatic abdominopelvic malignancies are limited, and these patients have short lifespan. The purpose of our study is to examine outcomes of combined open radiofrequency ablation (RFA) and surgical debulking of otherwise unresectable tumors. Methods: Consecutive 50 patients were identified from an Institutional Review Board (IRB)-approved database undergoing ablation for unresectable abdominopelvic malignancies via conventional surgical methods in a single institution between 07/2003 and 09/2009. Patients were selected for debulking if they had a dominant mass that caused significant symptoms. Results: Sixteen patients had primary tumors, and 34 presented with a recurrent/metastatic malignancy. The primary tumors were abdominopelvic sarcomas (eight patients), large desmoids (two), colorectal cancer (CRC) (two), and gastric cancer, mucinous cystic pancreatic neoplasm, gastrointestinal stromal tumor (GIST), and carcinoid (one each). The recurrent/metastatic tumors were CRCs (16 patients), abdominopelvic sarcomas (12), and GIST, prostate cancer, bladder cancer, melanoma, adrenal cancer, and pseudomyxoma peritonei recurrences (1 each). Twenty-two patients were alive and 28 died as of September 2009. Median survival for patients who died was 9.5months and for patients who were alive was 22months. Patients with primary tumors had 5-year survival of 18% compared with no survivors at 5years in the recurrent/metastatic group (P = 0.002). Conclusions: Thermosurgical ablation of otherwise unresectable primary tumors and recurrent/metastatic abdominopelvic malignancies is feasible in selected cases. Patients with ablated primary tumors have a survival advantage over patients who have ablation for recurrent/metastatic disease. Society of Surgical Oncology, 2010 Gajdos Csaba Department of Surgery, GITES Division, University of Colorado at Denver, Denver, CO, USA aut MacDermott Tracey Department of Surgery, GITES Division, University of Colorado at Denver, Denver, CO, USA aut McCarter Martin Department of Surgery, GITES Division, University of Colorado at Denver, Denver, CO, USA aut Pearlman Nathan Department of Surgery, GITES Division, University of Colorado at Denver, Denver, CO, USA aut Annals of Surgical Oncology Springer-Verlag 18/5(2011-05-01), 1267-1273 1068-9265 18:5<1267 2011 18 10434 https://doi.org/10.1245/s10434-010-1467-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1467-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gajdos Csaba Department of Surgery, GITES Division, University of Colorado at Denver, Denver, CO, USA aut NATIONALLICENCE 700 1- MacDermott Tracey Department of Surgery, GITES Division, University of Colorado at Denver, Denver, CO, USA aut NATIONALLICENCE 700 1- McCarter Martin Department of Surgery, GITES Division, University of Colorado at Denver, Denver, CO, USA aut NATIONALLICENCE 700 1- Pearlman Nathan Department of Surgery, GITES Division, University of Colorado at Denver, Denver, CO, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/5(2011-05-01), 1267-1273 1068-9265 18:5<1267 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer